Drug intelligence / Profile preview

HMPL-662

Development stage: Unknown
Lead developer: Inmagene Biopharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

HMPL-662 is a small molecule inhibitor of Receptor-Interacting Serine/Threonine-Protein Kinase 1 (RIPK1), a protein that plays a critical role in mediating necroptosis (programmed inflammatory cell death) and the production of pro-inflammatory cytokines. Developed by HUTCHMED, the compound was the subject of a licensing agreement with Inmagene Biopharmaceuticals for non-oncology indications, including inflammatory and autoimmune diseases. However, Inmagene terminated its rights to HMPL-662 in April 2023. The drug aims to treat conditions where RIPK1-mediated inflammation and cell death are pathogenic.

Targets

RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)

Beyond the preview

Go deeper on HMPL-662.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HMPL-662.

Explore the full profile